PH102 is our GPC3-targeted IT-ACTS therapy revolutionizing solid tumor treatment. It uniquely reprograms the tumor microenvironment, showing exceptional preclinical efficacy and safety.
tumor targeting
Our GPC3-Targeted IT-ACTS Therapy
GPC3 is an attractive target for immunotherapy due to its high expression in liver cancer and lack of expression in normal tissues. However, targeting solid tumors with CAR T-cell therapies has been challenging, as solid tumors often evade immune killing through multiple mechanisms of resistance.
Triple action platform
Unlocking Potent Anti-Tumor Responses
Our lead candidate harnesses the power of IT-ACTS in a GPC3-targeted chimeric antigen receptor (CAR) T-cell therapy specifically designed to tackle multiple critical pathways of immunotherapy resistance in liver cancer. By actively enhancing the activation and persistence of T-cells, natural killer (NK) cells, and dendritic cells within the hostile tumor microenvironment, while simultaneously reducing immunosuppressive signals and boosting tumor infiltration, this triple-action platform maximizes the anti-tumor potential of CAR T-cells.
In preclinical models of the most aggressive and lethal cancer subtypes, this IT-ACTS-based cell therapy has demonstrated exceptional efficacy, showing robust and durable anti-tumor responses across multiple solid tumor settings. Its unprecedented persistence, deep tumor infiltration, and ability to resist immunosuppressive pathways result in enhanced efficacy and improved safety, even from a single dose. To date, we have observed no off-target effects and only minimal on-target, off-tumor effects, setting the stage for a confident transition into clinical trials.
engineered to overcome
A First-In-Class & Versatile Approach
Although many CAR T-cell therapies encounter difficulties in addressing solid tumors, often due to immunosuppression and insufficient tumor infiltration, our IT-ACTS-based candidate has been specifically engineered to overcome these hurdles by directly targeting the key mechanisms of immune evasion. Unlike conventional CAR T therapies that suffer from limited persistence and immune exhaustion, this next-generation approach employs unique targeting and activation strategies that support sustained responses in hard-to-treat cancers.
The versatile design of our IT-ACTS-based therapy also lends itself to a wide range of solid tumor indications, whether used as a standalone treatment or in combination with immune checkpoint inhibitors, vaccines, and other immunotherapy approaches. By employing its triple-action mechanism, this therapy transcends the limitations of traditional CAR T-cell treatments, offering a compelling new avenue for combating solid tumors.
.avif)
